Phase 2 Lung Cancer Trial, Recruiting NCT07085182 Sponsor: Zibo Municipal Hospital Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT07085182
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any gender)
  • You are reasonably active and able to care for yourself, even if you cannot do heavy physical work (confirm with trial site what this means for your situation)
  • You have been diagnosed with a specific type of advanced lung cancer (stage IIIB/C or stage IV, non-squamous non-small cell lung cancer), confirmed by a tissue or cell sample
  • You have not yet received any treatment aimed at treating the cancer throughout your whole body

Who may not be able to join:

  • You have an autoimmune disease (a condition where your immune system attacks your own body) that is not currently under control
  • You have had an autoimmune reaction in the past 6 months that has not improved or is unstable, such as untreated or unstable lung inflammation, thyroid problems, or heart muscle inflammation
  • Your cancer has been found to have certain specific gene changes (such as EGFR, ALK, BRAF, ROS1, RET, or MET mutations or rearrangements)
  • You have already received systemic cancer treatment, or you received pre- or post-surgery cancer treatment and your cancer came back within 3 months of finishing that treatment
  • You are known to be allergic to the study drug or any of its ingredients
  • You are pregnant or breastfeeding, or you are a woman who could become pregnant and your pregnancy test at the start of the trial is positive
  • You are a woman who could become pregnant, or a man who plans to have children, and you are unwilling to use effective contraception throughout the trial and for 6 months after it ends
  • You have other health conditions or circumstances that your doctor feels would make it unsafe or unsuitable for you to take part in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zibo Municipal Hospital
Registry
ClinicalTrials.gov
Start date
13 January 2024
Est. completion
10 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov